
SITC – JITC Has Reached an Impact Factor of 10.6 and a CiteScore of 17.8 in 2024!
Society for Immunotherapy of Cancer (SITC) posted on LinkedIn:
“SITC is proud to share that the Journal for ImmunoTherapy of Cancer (JITC) has reached an Impact Factor of 10.6 and a CiteScore of 17.8 in 2024!
As an open access, peer-reviewed journal, JITC is committed to serve as a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Explore the latest high-impact articles:
Authors: Gyeong Dae Kim, So-I Shin, Pureum Sun, Jeong Eun Lee, Chaeuk Chung, Yea Eun Kang, Da Hyun Kang, Jihwan Park
Authors: Dandan Zhu, Zeying Li, Huolun Feng, Jiabin Zheng, Xiao Xiao, Zuda Huang, Liangying Zheng, Jieqing Guo, Fa Ling, Yong Li, Fan Xing
3. Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy.
Authors: Salomé S. Pinho, Matthew S. Macauley, Heinz Läubli
Authors: Alia D Zander, Rossin Erbe, Yan Liu, Ailin Jin, Seung Won Hyun, Sayantoni Mukhopadhyay, Ben Terdich, Mario G Rosasco, Nirali Patel, Brett M Mahon, A Kate Sasser, Michelle A Ting-Lin, Halla Nimeiri, Justin Guinney, Douglas Adkins, Matthew Zibelman, Kyle A Beauchamp, Chithra Sangli, Michelle M Stein, Timothy Taxter, Timothy Chan, Sandip P Patel, Ezra E W Cohen.”
More posts featuring Society for Immunotherapy of Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023